Beta Bionics (NASDAQ:BBNX) CFO Sells $127,559.25 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the sale, the chief financial officer directly owned 159,378 shares in the company, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The shares were sold at an average price of $17.05, for a total value of $87,023.20.

Beta Bionics Stock Down 2.5%

NASDAQ BBNX opened at $19.42 on Friday. The company has a market cap of $873.71 million, a price-to-earnings ratio of -11.77 and a beta of 3.37. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The business’s fifty day moving average is $17.17 and its 200 day moving average is $13.65.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million during the quarter. On average, research analysts anticipate that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its holdings in Beta Bionics by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after acquiring an additional 931 shares during the period. Deutsche Bank AG lifted its stake in shares of Beta Bionics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,296 shares during the period. Summit Securities Group LLC acquired a new position in shares of Beta Bionics in the 4th quarter valued at about $52,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Finally, Verition Fund Management LLC grew its stake in Beta Bionics by 4.0% during the third quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock worth $940,000 after purchasing an additional 1,823 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on BBNX shares. Bank of America reduced their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. The Goldman Sachs Group boosted their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. UBS Group began coverage on Beta Bionics in a research report on Tuesday, July 28th. They set a “buy” rating and a $22.00 target price for the company. Truist Financial upped their price target on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.10.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.